Improved Process For Preparing Pure Valsartan

Matrix Laboratories Ltd
Granted App No 1383/CHE/2007 Patent 276022 Chemical

Patent information

IP India · live record
Application number
1383/CHE/2007
Filing date
27 June 2007
Status
Granted
Legal status
Ceased
Publication number
02/2009
Publication type
INA
Invention field
Chemical
Patent number
276022
Grant date
28 September 2016
Next renewal due
28 June 2021Overdue

Abstract

An improved process for the preparation of substantially pure valsartan employing suitable reagents such as chelating agent and reaction conditions.

Applicants

1
India
MATRIX LABORATORIES LTD 1-1-151/1, IV FLOOR SAIRAM TOWERS ALEXANDER ROAD SECUNDERBAD 500 003

Inventors

4
India
JAKKA DEVENDRA RAOPLOT NO 34A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL MEDAK DIST HYDERABAD 500 055
India
MR. KATUKURI ARAVIND KUMARPLOT NO 34A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL MEDAK DIST HYDERABAD 500 055
India
MR. DAMMALAPATI VENKATA LAKSHMI NARASIMHA RAOPLOT NO 34A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL MEDAK DIST HYDERABAD 500 055
India
DR. OMDUTT TYAGIPLOT NO 34A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL MEDAK DIST HYDERABAD 500 055

Specification

Show full textCollapse

Improved Process for preparing Pure Valsartan Field of the Invention The invention in general relates to process for preparing substantially pure valsartan. More particularly, but without restriction to the particular embodiments herein after described in accordance with the best mode of practice, this invention relates to an improved process for the preparation of Substantially pure valsartan employing suitable reagents and reaction conditions. Background of the Invention Valsartan, N-(l-oxopentyl)-N-[[2'-(lH-tetrazol-5-yl)[l,r-biphenyl]-4yl]methyl]-L-valine, is a known anti-hypertensive agent having the following formula (I):

Valsartan is a non-peptide, orally active, specific angiotensin II antagonist, useful in the treatment of hypertension and is commercially available in the market under the brand name DIOVAN™ as 40, 80, 160 and 320 mg tablets. Valsartan, its pharmaceutically acceptable salts, pharmaceutical compositions comprising valsartan and their use in treating high blood pressure and cardiac insufficiency are disclosed in US 5,399,578 along with its preparation as depicted in scheme 1.

Briefly, the process for the preparation of Valsartan comprises the condensation of compound of formula IV with Valeryl chloride of formula III in the presence of triethylamine and dichloromethane followed by flash chromatography, to give the compound of formula II. The compound of formula II during tetrazole formation is undergo reaction with tributyltin azide and then subsequently hydrolysis using base like sodium hydroxide followed by flash chromatography gives Valsartan of formula I. The preparation of Valsartan according to the scheme reported above is very complicated and not commercially viable. The synthetic process which involves, inter-alia the use of tributyltin azide leads to increase the tin content in final product as an impurity approx. 20 ppm. It would therefore be highly desirable to provide a process the preparation of Substantially pure valsartan, which is commercially viable as well as reduces/removes the contamination of tin content in the final product Le, Valsartan.

It has now been found an alternative process for the preparation of substantially pure Valsartan which fulfills the above mentioned requirements. Summary of the Invention It is, therefore, an object of the present invention to improve upon limitations in the prior art. These and other object are attained in accordance with the present invention provide wherein there is provided embodiment of an improved process for the preparation of substantially pure Valsartan. In accordance with one preferred embodiment of the present invention, there is provided a process for the preparation of valsartan free from tin content. In accordance with another preferred embodiment of the present invention, there is provided a process for the preparation of valsartan using the chelating agent. Detailed Description of the Invention The disclosed embodiment of the present invention deals with a process for producing substantially pure Valsartan by using chelating agent (scheme 2).

The present invention in its aspect is a new, improved, economically and industrially feasible method for preparing substantially pure Valsartan. Valsartan obtained by the process of the invention is in fact substantially pure, and in particular free from tin

content. The expression "substantially pure" means a purity degree equal to or higher than 99% and having a tin content in said contaminants equal to or lower than 5 ppm. The compound of formula II is treated with tributyltin azide in a solvent such as xylene, toluene or mixture thereof at refluxing temperature for a period of 18-36 hrs preferably 24 hrs. The reaction mixture is then cooled to 0-40, preferably 25-35 followed by quenching with an aqueous base. The base is selected from the group consisting of alkali metal hydroxide or alkaline earth metal hydroxide, preferably sodium hydroxide and potassium hydroxide. The isopropyl ether is added to the reaction mixture under stirring for a period of 6-12 hrs, preferably 8-10 hrs. The organic layer is separated and then pH of the aqueous layer is adjusted with hydrochloric acid to 6.0-8.0 followed by treatment with charcoal. The reaction mixture is filtered followed by washing with an organic solvent. The organic solvent used herein is selected from the group consisting of halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride. Chelating agent is added to the aqueous layer and stirred for period of 15-45 min, preferably 30 min. The chelating agent used herein is selected from the group consisting of but not limited to ethylenediamine tetraacetic acid (EDTA), Diethylenetriaminepentaacetic acid; Diethylenetriamine-N,N,N',N',N"-pentaacetic acid (DTPA) and N,N-bis(carboxymethyl)glycine (NTA). The halogenated hydrocarbon is added to the reaction mixture followed by maintaining the pH to 3.0-5.0, preferably 4.0-4.5 with 10% hydrochloric acid and stirred. The halogenated hydrocarbon used herein is dichloromethane, chloroform and carbon tetrachloride, preferably dichloromethane. Layers are separated and organic layer is dried followed by evaporation to dryness to get residue. The obtained residue is then taken in ethyl acetate and optionally treated with charcoal and followed by cooling to get substantially pure valsartan. The compound of formula II can be prepared from any of the prior art process for the preparation of valsartan.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. The present invention can be illustrated in one of its embodiment by the following non-limiting examples. Example 1 Compound of formula II (50 gm) was treated with tributyltin azide prepared from reaction of tributyltin chloride (81 gm) and sodium azide (25 gm) in water (62 ml) and extracted in dichloromethane] in xylene at 25-30 under N2 atmosphere under refluxed for 24 hrs. After completion of the reaction, mixture was cooled to room temperature and quenched with aqueous potassium hydroxide (53.8 gm in 800 ml water) with stirring. The isopropyl ether (65 ml) was added to the reaction mixture and stirred followed by the layer separation. Aqueous layer was then treated with charcoal (7 gm) and filtered and washed with dichloromethane (3 x 50 ml). The pH of the aqueous layer was adjusted to 6.8-7.2 using hydrochloric acid and then treated with charcoal (7 gm) and filtered. EDTA (5 gm) was added to the aqueous solution and pH was adjusted again to 4.0-4.5 using hydrochloric acid and stirred. The aqueous layer was extracted with dichloromethane (3 x 66.5 ml) and then organic layer was washed with 10% sodium chloride solution. The organic layer was evaporated to dryness to get residue and then residue was taken in ethyl acetate (25 ml) and raised the temperature to 40-45°C followed by treatment with charcoal (5 gm) and filtered. The reaction mixture was cooled to 18-22°C and filtered the residue under nitrogen atmosphere. The residue was washed with ethyl acetate and dried. Certain modifications and improvements of the disclosed invention will occur to those skilled in the art without departing from the scope of invention, which is limited only by the appended claims.

We claim: (1) Substantially pure Valsartan with a tin content equal to or less than 5 ppm. (2) An improved process for the preparation of Valsartan, wherein a compound of formula II is reacted with tributyltin azide in solvent medium, followed by treatment with chelating agent during workup to get substantially pure Valsartan. (3) The improved process for the preparation as claimed in claim 2, which comprises:

(a) reacting compound of formula II with tributyltin azide in solvent; (b) quenching the reaction with base; (c) treating with charcoal and washed with organic solvent; (d) adjusting the pH of the solution to 6.0-8.0 using an acid and treated with charcoal and filtered; (e) adding the chelating agent to the reaction mixture; (f) adjusting the pH 3.0-5.0 using an acid; (g) extracting the aqueous layer with organic solvent; (h) evaporating the solvent to get residue; (i) taking the residue in ethyl acetate and cooled; (j) filtering the precipitates and dried. (4) The process according to claim 3, wherein solvent used is xylene, toluene or mixture thereof. (5) The process according to claim 3, wherein base is alkali metal hydroxide and alkaline earth metal hydroxide. (6) The process according to claim 5 wherein base is sodium hydroxide and potassium hydroxide. (7) The process according to claim 3, wherein organic solvent is dichloromethane, chloroform and tetrachloromethane.

(8) The process according to claim 3, wherein acid used is hydrochloric acid. (9) The process according to claim 3, wherein chelating agent used is ethylenediamine tetraacetic acid.

Documents

Sign in to open
Application documents
1 1383-CHE-2007 FORM-3 07-01-2010.pdf 07 Jan 2010
2 1383-CHE-2007 FORM 18 21-07-2010.pdf 21 Jul 2010
3 1383-che-2007-form 3.pdf 03 Sep 2011
4 1383-che-2007-form 1.pdf 03 Sep 2011
5 1383-che-2007-description(complete).pdf 03 Sep 2011
6 1383-che-2007-correspondnece-others.pdf 03 Sep 2011
7 1383-che-2007-claims.pdf 03 Sep 2011
8 1383-che-2007-abstract.pdf 03 Sep 2011
9 1383-che-2007 correspondance others.pdf 03 Sep 2011
10 1383-CHE-2007 FORM-13 05-12-2011.pdf 05 Dec 2011
11 1383-CHE-2007 FORM-3 16-10-2012.pdf 16 Oct 2012
12 1383-CHE-2007 FORM-3 04-03-2013.pdf 04 Mar 2013
13 1383-CHE-2007 CORRESPONDENCE OTHERS 04-03-2013.pdf 04 Mar 2013
14 Examination Report Reply Recieved [07-01-2016(online)].pdf 07 Jan 2016
15 Description(Complete) [07-01-2016(online)].pdf 07 Jan 2016
16 1383-CHE-2007 EXAMINATION REPORT REPLY RECEIVED 07-01-2016.pdf 07 Jan 2016
17 1383-CHE-2007_EXAMREPORT.pdf 02 Jul 2016
18 description-----------Description_Granted 276022_ 28-09-2016.pdf 28 Sep 2016
19 claims--------------Claims_Granted 276022_ 28-09-2016.pdf 28 Sep 2016
20 abstract------------------Abstract_Granted 276022_ 28-09-2016.pdf 28 Sep 2016
21 Form27_License_15-02-2017.pdf 15 Feb 2017
22 Form27_License_12-03-2018.pdf 12 Mar 2018
23 1383-CHE-2007-RELEVANT DOCUMENTS [20-03-2019(online)].pdf 20 Mar 2019
24 1383-CHE-2007-RELEVANT DOCUMENTS [30-03-2020(online)].pdf 30 Mar 2020
25 1383-CHE-2007-RELEVANT DOCUMENTS [06-07-2021(online)].pdf 06 Jul 2021

ERegister / renewals

Ceased
3rd Renewed 05 Oct 2016 Period 27 Jun 2009 – 27 Jun 2010 · CBR 26214 · Certificate 17420 ₹4,000
4th Renewed 05 Oct 2016 Period 27 Jun 2010 – 27 Jun 2011 · CBR 26214 · Certificate 17421 ₹4,000
5th Renewed 05 Oct 2016 Period 27 Jun 2011 – 27 Jun 2012 · CBR 26214 · Certificate 17422 ₹4,000
6th Renewed 05 Oct 2016 Period 27 Jun 2012 – 27 Jun 2013 · CBR 26214 · Certificate 17423 ₹4,000
7th Renewed 05 Oct 2016 Period 27 Jun 2013 – 27 Jun 2014 · CBR 26214 · Certificate 17424 ₹12,000
8th Renewed 05 Oct 2016 Period 27 Jun 2014 – 27 Jun 2015 · CBR 26214 · Certificate 17425 ₹12,000
9th Renewed 05 Oct 2016 Period 27 Jun 2015 – 27 Jun 2016 · CBR 26214 · Certificate 17426 ₹12,000
10th Renewed 05 Oct 2016 Period 27 Jun 2016 – 27 Jun 2017 · CBR 26214 · Certificate 17427 ₹12,000
11th Renewed 05 Oct 2016 Period 27 Jun 2017 – 27 Jun 2018 · CBR 26214 · Certificate 17428 ₹24,000
12th Renewed 31 May 2017 Period 27 Jun 2018 – 27 Jun 2019 · CBR 19820 · Certificate 14692 ₹24,000
13th Renewed 20 Jun 2019 Period 27 Jun 2019 – 27 Jun 2020 · CBR 19751 · Certificate 26597 ₹24,000
14th Renewed 05 Jun 2020 Period 27 Jun 2020 – 27 Jun 2021 · CBR 17760 · Certificate 30960 ₹24,000